ClinicalTrials.gg

Program

tebapivat

Also written as “Tebapivat”, “[14C]-tebapivat” and “[13C2,15N3]-tebapivat”.

Its studies are mostly in Anemia, Sickle Cell · Myelodysplastic Syndromes, led by Agios Pharmaceuticals.

Furthest: phase 2, since Jul 26, 20224 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals42 open or runningphase 2since Jul 26, 2022Jul 15, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2020First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04536792 · 122 enrolled · United States, Denmark, Spain
  2. Jul 26, 2022Phase 2 study in Myelodysplastic SyndromesNCT05490446 · 87 enrolled · United States, Australia, Austria and more
  3. Dec 17, 2024Phase 1 study in Healthy ParticipantsNCT06745271 · 8 enrolled · United States
  4. Apr 10, 2025Phase 2 study in Anemia, Sickle CellNCT06924970 · 59 enrolled · United States, Belgium, Canada and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06924970Anemia, Sickle Cell · United States, Belgium, Canada and more2Active, not recruitingMay 12, 202659
NCT06745271Healthy Participants · United States1CompletedFeb 21, 20258
NCT05490446Myelodysplastic Syndromes · United States, Australia, Austria and more2Active, not recruitingMar 17, 202687
NCT04536792Anemia, Sickle Cell · United States, Denmark, Spain1CompletedDec 19, 2023122

How it is read

Names in the registry

  • “Tebapivat”, 2 entries
  • “[14C]-tebapivat”, 1 entry
  • “[13C2,15N3]-tebapivat”, 1 entry
  • “AG-946”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.